Clinical Study

Adalimumab Treatment in Biologically Naïve Crohn’s Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement

Table 2

The relation between MUC5AC immunostaining, CDAI, CRP and CDEIS in the CD patients having the ADA treatment as the first TNF- inhibitor ( ).

CDAICRPMUC5ACCDEISClinical course after 52 weeks
0 w12 w52 w0 w12 w52 w0 w12 w52 w0 w12 w52 w

CD-ADA-1ModerateRemissionRemission+2223+3+3+The seton operation was performed, since anal fistula worsened.
CD-ADA-2MildRemissionMild+1021+1+3+Flare up (CRP = 2.11↑)
CD-ADA-3ModerateRemissionRemission+1122+1+2+Flare up (CRP = 6.09↑) after 78 weeks
CD-ADA-4ModerateMildRemission+2202+2+1+Maintenance of clinical remission
CD-ADA-5MildRemissionRemission+++223+1+Maintenance of clinical remission
CD-ADA-6ModerateRemissionRemission2103+1+MHMaintenance of clinical remission
CD-ADA-7ModerateRemissionRemission++2003+3+1+Maintenance of clinical remission
CD-ADA-8ModerateRemissionRemission++1003+MHMHMaintenance of clinical remission
CD-ADA-9ModerateRemissionRemission+1003+1+1+Maintenance of clinical remission
CD-ADA-10MildRemissionRemission++0003+MH2+Maintenance of clinical remission
CD-ADA-11MildRemissionRemission+++0003+1+1+Maintenance of clinical remission (CRP was judged to be negative after 78 weeks.)
CD-ADA-12ModerateRemissionRemission0003+1+2+Maintenance of clinical remission
CD-ADA-13MildRemissionRemission0002+1+1+Maintenance of clinical remission
CD-ADA-14ModerateRemissionRemission+003+MHMaintenance of clinical remission
CD-ADA-15ModerateRemissionRemission+0003+MHMHMaintenance of clinical remission

CDAI: Remission: score < 150; Mild: 150 ≤ score < 220; Moderate: 220 ≤ score < 450; Severe: score ≥ 450.
CRP: −: ≤0.30 mg/dL; +: >0.30 mg/dL.
CDEIS: non-activity (mucosal healing: MH): CDEIS < 3; mild active stage (1+): 3 ≤ CDEIS < 9; moderate active stage (2+): 9 ≤ CDEIS < 12; severe active stage (3+): 12 ≤ CDEIS.